Back HCV Treatment

HCV Treatment

FDA Approves Gilead's Vosevi Combo Pill for Hepatitis C Re-treatment

On July 18, the U.S. Food and Drug Administration(FDA) approved Gilead Sciences' Vosevi, a new once-daily combination pill containing sofosbuvir, velpatasvir, and voxilaprevir. Vosevi was approved as "salvage therapy" for people with all hepatitis C virus (HCV) genotypes who were not previously cured with prior direct-acting antiviral therapy.

alt

Read more:

HR17: Indonesian Buyers Club Helps People Obtain Generic Hepatitis C Treatment

A community-led buyers club in Indonesia has helped more than 100 people get generic direct-acting antiviral drugs to treat hepatitis C and is seeing a high cure rate, according to a presentation at the 25th Harm Reduction International Conference this month in Montreal.

alt

Read more:

HR17: Hepatitis C Virus Reinfection Is Uncommon After Being Cured with DAAs

Most people on opiate substitution therapy were successfully treated for hepatitis C with an interferon-free regimen of grazoprevir/elbasvir (Zepatier), and only a small number became reinfected during 3 years of follow-up, researchers reported at the 25th Harm Reduction International Conference this week in Montreal.

alt

Read more:

Coverage of the 2017 Harm Reduction International Conference

HIVand Hepatitis.com coverage of the 2017 Harm Reduction International Conference, May 14-17, 2017, in Montreal.

Full coverage listing

HR17 website

5/31/17

alt

EASL 2017: Triple Combination Cures Most Hepatitis C Patients with Prior DAA Failure

Almost all people with genotype 1 hepatitis C who were previously unsuccessfully treated with a course of interferon-free direct-acting antiviral therapy achieved sustained response when retreated with a 3-drug combination being developed by Merck, researchers reported at the EASL International Liver Congress last month in Amsterdam.

alt

Read more: